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The clinical expert consensus statement on takotsubo syndrome (TTS) part II focuses on the diagnostic workup, outcome, and
management. The recommendations are based on interpretation of the limited clinical trial data currently available and experience of
international TTS experts. It summarizes the diagnostic approach, which may facilitate correct and timely diagnosis. Furthermore,
the document covers areas where controversies still exist in risk stratification and management of TTS. Based on available data the
document provides recommendations on optimal care of such patients for practising physicians.
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Diagnostic workup
A diagnostic algorithm for takotsubo syndrome (TTS) is proposed by
the expert committee (Figure 1). Patients presenting with ST-segment
elevation should undergo urgent coronary angiography (CAG) with
left ventriculography to exclude acute myocardial infarction (AMI). In
patients with non ST-segment elevation the InterTAK Diagnostic
Score can be considered. While an InterTAK Score <_70 points sug-
gests a low to intermediate probability of TTS, a score >_70 indicates a
high probability for the presence of TTS. Patients with a low probabil-
ity should undergo CAG with left ventriculography, while in patients
with a high score transthoracic echocardiography (TTE) should be
considered. In the absence of a circumferential ballooning pattern
CAG is recommended. In stable patients with circumferential balloon-
ing pattern coronary computed tomography angiography (CCTA) is
favoured to exclude coronary artery disease (CAD). In unstable pa-
tients, typical complications of TTS such as left ventricular outflow
tract obstruction (LVOTO) should be determined with TTE and
CAG to safely rule out AMI. In patients with normal coronaries on
CCTA or CAG and typical ballooning patterns without ‘red flags’ of
acute infectious myocarditis TTS is the most likely diagnosis and can
be confirmed after follow-up echocardiography. In case of positive
‘red flags’ of acute infectious myocarditis cardiac magnetic resonance
(CMR) should be performed to confirm the diagnosis.
Electrocardiogram
The initial electrocardiogram (ECG) is abnormal in most patients with
TTS usually demonstrating ischaemic ST-segment elevation, T-wave
inversion, or both.1–4 In the InterTAK Registry, ST-segment elevation
was present in 44%, ST-segment depression in 8%, T-wave inversion
in 41%, and left bundle branch block in 5%.2 As in acute coronary
syndrome (ACS), the ECG in TTS demonstrates temporal evolution
typically with resolution of initial ST-segment elevation (if present), fol-
lowed by progressive T-wave inversion and QT interval prolongation
2048 J.-R. Ghadri et al.
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over several days, with subsequent gradual resolution of T-wave in-
version and QT interval prolongation over days to weeks.5–8 The ini-
tial and subsequent ECG findings are influenced by several variables,
including the geographic pattern of left ventricular (LV) ballooning,
presence or absence of right ventricular (RV) ballooning, time from
symptom onset to presentation, presence of myocardial oedema, and
recovery rate of myocardial cellular function.
ST-segment elevation
As with ST-segment elevation myocardial infarction (STEMI), the loca-
tion and extent of ST-segment elevation in TTS corresponds to the
anatomic location of myocardial injury, most often the mid and apical
LV segments.2 Consequently, ST-segment elevation usually involves
precordial, lateral, and apical ECG leads, closely resembling that of an-
terior STEMI due to left anterior descending coronary occlusion.9,10
Lead -aVR (inverse of aVR) representing þ30 in the frontal plane is
generally aligned with the LV apex, and can be assembled with other
leads to create an ‘ECG map’, useful in comparing the ST-segment ele-
vation pattern of TTS with that of anterior STEMI.3,9,11,12 ST-segment
elevation in TTS is centred on precordial leads V2–V5 and limb leads
II and aVR, whereas in anterior STEMI the ST-segment elevation
centres on precordial leads V1–V4 and limb leads I and aVL. Several
ECG criteria with high sensitivity and specificity have been proposed
to reliably distinguish TTS from anterior STEMI.3,12–14 Most focus on
ST-segment elevation in the precordial leads, particularly lead V1, as
ST-segment elevation in this lead is less pronounced in TTS than in
anterior STEMI.9,10,12 ST-segment elevation limited to the inferior
leads (II, III, aVF) is distinctly uncommon in TTS. Despite these differ-
ences, overlap exists and an urgent coronary angiogram is necessary
to differentiate TTS from STEMI with certainty.9–11
T-wave inversion and QT interval prolongation
Progressive T-wave inversion and QT interval prolongation is a com-
mon ECG finding in TTS. In patients with delayed presentation, these
CAD
Chest pain and/or Dyspnea#
ECGST-elevation Non ST-elevation
InterTAK Diagnostic Score§
stniop 52xes elameF
Emotional stress 24 points
Physical stress 13 points
No ST-segment depression* 12 points
Psychiatric disorders 11 points
Neurologic disorders 9 points
QTc prolongation 6 points
Coronary angiography
≤ 70 points
Low/intermediate 
probability of TTS
> 70 points
High probability
of TTS
ACS
TTE
Apical, midventricular, or 
basal ballooning with 
circumferential pattern
Distal LAD flow 
visualization
Red flags of acute infectious myocarditis:
- Signs and/or symptoms of viral infections
- Elevated ESR and/or CRP
- Pericardial effusion
Check the presence of: 
LVOTO
Significant MR
RV involvement
TTE follow-up
CCTA
Coronary culprit 
lesions, which explain 
the whole RWMA? 
CMR
TTS
ACS
Acute infectious myocarditis
TTS confirmed
Stable patient
Persistend RWMA?
Yes
No
Yes
Yes
No
No
Yes
Yes
No
Yes
No
No
Yes
Figure 1 Diagnostic algorithm of takotsubo syndrome. #Applied to patients who are seeking medical emergency departments with e.g. chest pain
and/or dyspnoea. §The InterTAK Diagnostic Score did not include patients with pheochromocytoma induced takotsubo syndrome in which atypical
pattern are more frequently noted. *Except in lead aVR. ACS, acute coronary syndrome; CAD, coronary artery disease; CCTA, coronary computed
tomography angiography; CMR, cardiac magnetic resonance; CRP, c-reactive protein; ECG, electrocardiogram; ESR, erythrocyte sedimentation rate;
InterTAK, International Takotsubo Registry; LAD, left anterior descending coronary artery; LVOTO, left ventricular outflow tract obstruction; MR,
mitral regurgitation; QTc, QT-time corrected for heart rate; RV, right ventricle; RWMA, regional wall motion abnormality; TTE, transthoracic echo-
cardiography; TTS, takotsubo syndrome.
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..changes may be present on admission in the absence of ST-segment
elevation, and can be the only detectable ECG changes and therefore
important for the diagnosis. The geographic distribution of T-wave in-
version closely parallels that of ST-segment elevation and may be an
electrophysiological manifestation of myocardial stunning. In TTS,
T-wave inversion is often more prominent and more broadly distrib-
uted than in ACS. Furthermore, T-wave inversion is associated with
presence of myocardial oedema, and may persist for several months
even after LV contractile recovery, thus leaving an electrophysiolo-
gical footprint of the TTS event.5,15–19 QT interval prolongation pro-
vides a substrate for torsades de pointes ventricular tachycardia and
may be a prognostic marker for sudden cardiac death16,17
Other electrocardiogram findings
Anterior Q-waves (or poor R-wave progression) without accom-
panying ST-segment elevation or T-wave inversion, a pattern
sometimes referred to as ‘anterior infarction, age indeterminate’
occurs with some frequency in TTS. Pathologic Q-waves are less
frequently encountered in TTS than anterior STEMI (15% vs.
69%).14 In TTS, as in anterior STEMI, Q-waves may occur in the
acute phase, and regress rapidly with R-wave re-appearance, con-
sistent with electrical stunning.20,21 Both J-wave and/or frag-
mented QRS complexes have been reported acutely, the former
associated with death from cardiac causes and/or ventricular
tachyarrhythmia.22 Low QRS voltage likely representing
myocardial oedema is prevalent in TTS.23 Left bundle branch
block is present in around 5% of patients.2 ST-segment depression
is uncommon, occurring in fewer than 10% of TTS patients but in
over 30% of ACS patients,2 therefore, the presence of ST-
segment depression may suggest ACS.
InterTAK Diagnostic Score
The InterTAK Diagnostic Score was developed by the International
Takotsubo Registry to provide clinicians a model to assess the likeli-
hood of TTS diagnosis. The criteria that make up the InterTAK
Diagnostic Score are based on clinical features and ECG to predict the
probability of the presence of TTS and to distinguish TTS from ACS
(Figure 1, Figure 2A).24 The InterTAK Diagnostic Score comprises seven
parameters [female sex, emotional trigger, physical trigger, absence of
ST-segment depression (except in lead aVR), psychiatric disorders,
neurologic disorders, and QT prolongation] ranked by their diagnostic
importance with a maximum attainable score of 100 points
(Figure 2A).24 All parameters can be easily obtained in the emergency
department and do not require an imaging modality.24
Depending on the disease prevalence this means that patients with
30 score points have a predicted probability of <1%, while patients with
50 points have a probability of 18%, and patients with a score value >70
points have a probability of90% of suffering from TTS (Figure 2B).24
Figure 2 InterTAK Diagnostic Score. Predictors for diagnosing takotsubo syndrome by multiple logistic regression analysis. Odds ratios of the
parameters female sex, emotional trigger, physical trigger, absence of ST-segment depression, psychiatric disorders, neurologic disorders, and QTc
prolongation, which were chosen to build the InterTAK Diagnostic Score. *Except in lead aVR (A). Sigmoid curve shows the estimated prevalence of
takotsubo syndrome in clinical practice (B). Modified and reprinted with permission from Ghadri et al.24. CI, confidence interval; OR, odds ratio; QTc,
QT-time corrected for heart rate; TTS, takotsubo syndrome.
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Biomarkers
Markers of myocardial necrosis
Virtually all cases of TTS exhibit evidence of myocardial necrosis. On ad-
mission, troponin values are usually equally elevated compared to ACS,
however, peak values are substantially lower compared to the classical
ACS.2 High admission troponin levels are a predictor for a worse
in-hospital outcome.2 Typically, there is only a slight increase in creatine
kinase.2 The extent of LV regional wall motion impairment generally
greatly exceeds that of associated myocardial necrosis biomarkers, likely
reflecting a large mass of reversibly injured (stunned) myocardium.
B-type natriuretic peptide and N-terminal prohormone
of brain natriuretic peptide
Takotsubo syndrome is frequently associated with a substantial increase
in the plasma levels of B-type natriuretic peptide (BNP) and N-terminal
prohormone of brain natriuretic peptide (NT-proBNP) reaching its
peak approximately 24–48 h after symptom onset25,26 as a reflection of
regional LV dysfunction. A gradual return of BNP/NT-proBNP towards
normal levels occurs within the next few months after presentation.27
The degree of NT-proBNP elevation appears directly related to:
(i) the degree of sympathetic overactivation (as reflected by norme-
tanephrine concentrations), (ii) peak C-reactive protein concentra-
tions (suggesting that BNP release might be at least in part of
inflammatory origin), and (iii) systolic LV dysfunction [as measured by
wall motion score index (WMSI)].25 Peak NT-proBNP levels also
vary with the extent of LV oedema as measured by CMR.28
Other potential biomarkers
Interleukin (IL)-6 levels appear less elevated while those of IL-7 are
more elevated in TTS compared with AMI.29 However, differences
between groups were small and unlikely to be of diagnostic utility.
Two recently published studies focused on the potential utility of
the release and circulation of certain microRNAs (miRNAs) in associ-
ation with TTS onset.30,31 Kuwabara et al.30 noted that elevation of
circulating miR-133a appeared to represent an early consequence of
myocardial injury, including TTS and AMI. However, subsequent ana-
lyses of cases of TTS (N= 36) and evolving STEMI (N= 27) suggested
that the elevation of miR-133a was more marked in STEMI than in
TTS. Furthermore, Jaguszewski et al. demonstrated that a unique sig-
nature including miR-1, miR-16, miR-26a, and miR-133a represents a
robust biomarker on admission and can be used to differentiate TTS
from STEMI patients.31 Furthermore, the up-regulation of miR-16
and miR-26a is known to be associated with stress- and affective dis-
orders.32–34
Especially in patients with biventricular involvement, it has been shown
that plasma concentrations of the stress-responsive cytokine growth dif-
ferentiation factor-15 increased more rapidly after the onset of TTS.35
Imaging
Coronary angiography and ventriculography
Although non-invasive imaging modalities are useful in the workup of
patients with TTS, final differential diagnosis from ACS requires coron-
ary angiogram, which is performed in the context of ST-elevation in pri-
mary percutaneous coronary intervention service. In case of suspected
TTS with coexisting and significant CAD, careful comparison of CAG
and biplane ventriculography in similar views is mandatory to search
for a perfusion-contraction mismatch.36,37 This comparison is essential
for distinguishing TTS from classical AMI in patients with wall motion
abnormalities and obstructive CAD. In this regard, it has been reported
that approximately one-third of patients with the classical apical bal-
looning show a small zone with preserved contractility in the most dis-
tal portion of the apex, which is described as the ‘apical nipple sign’.38
Furthermore, as LVOTO occurs in approximately 20% of patients with
TTS,39 haemodynamic assessment for the presence of a pressure-
gradient in the outflow tract as well as assessment of left ventricular
end-diastolic pressure are recommended. Figure 3A demonstrates ap-
ical ballooning pattern on left ventriculography.
Echocardiography
Echocardiography is the most used imaging tool to assess changes in
LV function such as symmetric regional wall motion abnormalities
(RWMAs).4 Different variants can be identified with echocardio-
graphy which include:
(1) Apical ballooning, hypo-, a-, or dyskinesia of mid-apical myocardial
segments is typical, sometimes associated with hypokinetic mid-seg-
ments.2,40 The anterior or entire interventricular septum, inferior
or midventricular anterolateral wall may also be involved.41,42 LV
twisting on 2D speckle-tracking imaging is reduced or reversed to
clockwise apical rotation and the rate of untwisting (a sensitive index
of regional diastolic dysfunction) is reduced in the acute phase.43
(2) Midventricular TTS featured by hypo-, a-, or dyskinesia of midven-
tricular segments, most often resembling a cuff.2,40,44,45
(3) Basal forms where only basal segments are involved2,40: This
phenotype is rare and appears commonly in patients with sub-
arachnoid haemorrhage,46 epinephrine-induced TTS47 or
phaeochromocytoma.48
(4) Focal TTS mostly involving an anterolateral segment has been
described.2,40 Differentiating this unusual TTS type from ACS or
myocarditis requires CMR.49
Right ventricular involvement is characterized by RV dilatation with
hypo- to akinesia of the free wall and apex in its isolated form.50,51
In TTS, LV wall motion abnormalities extend beyond the distribu-
tion of a single coronary artery territory, therefore systolic dysfunc-
tion appears ‘circular’ at speckle-tracking echocardiography.52
A WMSI >_1.75 with more than four dysfunctional segments identifies
TTS with 83% sensitivity and 100% specificity.53 Doppler estimation
of coronary artery flow ameliorates the diagnostic accuracy of wall
motion abnormalities,54 whereas adenosine may lead to dramatic im-
provements of global and regional LV function.41
Intravenous ultrasound contrast agents facilitate wall motion assess-
ment especially at the apex52 and constitute a useful method especially
in patients in whom CAG is not performed, mainly due to active bleed-
ing or other comorbid conditions that may imbalance the risk-benefit
ratio of CAG (see Cardiac computed tomography angiography sec-
tion). Myocardial opacification is reduced within dysfunctional seg-
ments with the transmural perfusion defects being more evident early
after TTS onset.55 Coronary flow reserve, assessed by transthoracic
Doppler echocardiography, is reduced to 1.6–2.6 at the levels of the
right and left coronary arteries56,57 and correlates with indices of LV
systolic but not diastolic function.58 In contrast to ischaemic cardiomy-
opathy, myocardial contraction does not improve with low-dose
dobutamine at the early stages.59,60 However, it has also been demon-
strated that low dose dobutamine stress echocardiography improved
Expert Consensus Document on Takotsubo Syndrome, Part II 2051
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..systolic left ventricular function by normalizing or improving the hypo-
kinetic segments.61 Moreover, in STEMI, viable myocardial segments
exhibit longitudinal shortening, while in TTS systolic lengthening (pas-
sive motion) is present initially and resolves at follow-up.62
Importantly, echocardiography allows detection of all acute TTS
complications. In LV apical ballooning, basal segments are hyperkinetic
and may cause dynamic LVOTO,63 mainly in patients with pre-existing
septal bulge64 which further reduces stroke volume and is associated
with mitral regurgitation (MR) due to systolic anterior motion of the
mitral leaflet (Figure 3B).63,65 Severe MR may also result from leaflet
tethering by displacement or dysfunction of papillary muscles. Mitral re-
gurgitation is estimated to be present in 14–25% of TTS patients.66
Advanced echocardiographic techniques such as speckle-tracking
imaging which reveals a paradoxical (dyskinetic) positive longitudinal
systolic strain of biventricular mid-apical segments.67 Echocardiogra-
phy also identifies covered rupture of the LV free wall68 as well
as thrombus formation within a dysfunctional LV apex69 or within
left-atrial appendage even in the absence of atrial fibrillation.70 Inde-
pendent predictors of adverse outcomes include low left ventricular
ejection fraction (LVEF), increased LV filling pressure, and moderate-
to-severe MR at 4–6 weeks.71,72
At peak, apical and anteroseptal akinesis with basal hyper-
contractility produces near-cavity obliteration.73
Typically, LV contractility recovers completely in 4–8 weeks.2,74
Some segments of the LV recover earlier than others, displaying
increased apical rotation, LV twisting and untwisting and recovered
global longitudinal strain.43,75 Resolution of LVOTO and MR76 occurs
in parallel with myocardial functional recovery. During TTS recur-
rence, the LV ballooning pattern may resemble the initial event77 or
alternatively, manifest as other variants.78
Cardiac computed tomography angiography
In the presence of life-threatening comorbid conditions such as ter-
minal malignancy, intracranial bleeding, advanced age with frailty and
bleeding diathesis, invasive CAG may pose a considerable risk for
complications. In a recent study by Murugiah et al.,79 a substantial pro-
portion of patients with TTS as a secondary diagnosis code did not
undergo CAG. The reasons for not performing CAG were not
Left Ventriculography 
.
Cardiac Magnetic Resonance Imaging 18F-FDG PET / 201TI SPECT
EchocardiographyA B
C D
3) 4) 5)
1) 2)
1) 2)2))3)2)1
1) 2)
3) 4)
6)5)
Figure 3 Apical ballooning illustrated by different imaging modalities. Typical takotsubo type with apical ballooning pattern during diastole (A.1)
and systole (A.2) on left ventriculography. Dashed lines indicate extent of wall motion abnormality (A.3). Modified and reprinted with permission
from Templin et al.2 Apical four-chamber view obtained by echocardiography showing apical ballooning and left ventricular cavity with bulging of the
basal interventricular septum (white arrow) (B.1). B.2 reveals left ventricular outflow tract obstruction by pulsed-wave Doppler interrogation.
Modified and reprinted with permission from Merli et al.100 Apical ballooning as illustrated by cardiac magnetic resonance imaging. The asterisks indi-
cate pericardial effusion (C.1) and yellow arrows (C.2) shows the region of akinesia. T2-weighted images on short-axis view demonstrates normal sig-
nal intensity of the basal myocardium (C.3) and global oedema of the mid and apical myocardium (C.4 and C.5). Modified and reprinted with
permission from Eitel et al.82 Metabolic imaging with positron emission tomography and 18F-flurodeoxyglucose (D.1, D.3, D.5) demonstrates
decreased uptake in the apex and midventricular segments. Perfusion imaging using single photon emission computed tomography with 201thallium
chloride (D.2, D.4, D.6) shows a smaller perfusion defect in the apex and midventricular segments. Reprinted with permission from Yoshida et al.98
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described but likely included the mentioned life-threatening comor-
bid conditions. In such patients, non-invasive CCTA may be an appro-
priate alternative to CAG. Coronary computed tomography
angiography provides information on both coronary artery anatomy
and regional LV contraction. Assessment of LV contraction by CCTA
requires image acquisition throughout the cardiac cycle and thus
higher radiation exposure. In patients with suspected recurrent TTS
and a previous CAG, CCTA may be a diagnostic alternative.
Furthermore, CCTA may be considered instead of CAG in the fol-
lowing circumstances: in stable patients with low suspicion of ACS,
suspected recurrent TTS, and patients with elevation of cardiac bio-
markers or ECG changes in association with acute critical illnesses
such as sepsis, intracranial disease (e.g. subarachnoid haemorrhage, is-
chaemic stroke), and other critical conditions known to be compli-
cated by TTS.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging cannot be used easily in the acute
setting of TTS, but is very useful in the subacute phase. In addition to
identification of typical RWMAs, CMR allows precise quantification of
RV and LV function, assessment of additional abnormalities/complica-
tions (i.e. pericardial and/or pleural effusion, LV and RV thrombi), and
characterization of myocardial tissue (i.e. oedema, inflammation, ne-
crosis/fibrosis) (Figure 3C).80,81 Recently, specific CMR criteria for TTS
diagnosis at the time of acute presentation were established which in-
clude the combination of typical RWMAs, oedema, and the absence
of evidence of irreversible tissue injury [late gadolinium enhancement
(LGE)].82 While LGE is usually absent and predicts complete normal-
ization of LV function, subtle fibrosis may be present and a sign of
worse outcomes.83–85 In most TTS patients, myocardial oedema is
present in regions with abnormal systolic function possibly due to in-
flammation, increased wall stress and/or transient ischemia82 and indi-
cative of the extent and severity of tissue injury.86 CMR is superior to
echocardiography for detection of RV involvement82 including iso-
lated RV TTS87 which may negatively impact outcome.88 Importantly,
absence of LGE in dysfunctional LV regions allows distinction between
TTS and other conditions including ACS (subendocardial or trans-
mural LGE corresponding to a vascular territory) and many cases of
acute myocarditis (frequent, but not universal presence of epicardial
or ‘patchy’ LGE). Therefore, CMR provides incremental value for the
differential diagnosis, and therapeutic decision-making in patients with
suspected TTS.89
Cardiac nuclear imaging
Both single photon emission computed tomography (SPECT, using
201thallium chloride or 99mtechnetium sestamibi) which provides
semi-quantitative information and position emission tomography
(PET, using 13N-ammonia 82Rubidium) which offers quantitative
measurements, have been used in TTS for assessment of perfusion,
metabolism, and innervation.
Perfusion imaging
Mild reduction of perfusion in dysfunctional segments using myocar-
dial perfusion scintigraphy has been noted in some studies, while
others reported normal perfusion.90–94 However, ‘myocardial
thinning’ in involved segments during the acute phase of TTS may
lead to a reduction in isotope counts because of the partial volume
effect, which may mimic reduction of perfusion on SPECT, but fol-
lowing correction for this factor on PET, blood flow in the thinned re-
gions (typically in the apex) is indeed maintained, while the normally
functioning (basal) segments show hyper-perfusion.95
Metabolic imaging
The role of metabolic imaging in the clinical setting has not been
determined and it has been performed mainly for research purpose
of investigating the pathophysiology of TTS, although it can provide
additional information about the diseased myocardium. Both SPECT
using 123I-b-methyl-iodophenyl pentadecanoic acid (which reflects
fatty-acid) and PET using 18F-flourodeoxyglucose (which reflect glu-
cose utilization) often show reduced metabolic activity in the im-
paired regions, while myocardial perfusion is often (near) normal.96,97
An example with apical TTS is shown in Figure 3D, revealing severely
reduced 18F-flourodeoxyglucose uptake in the apex despite only
slightly reduced perfusion as assessed with 201thallium chloride.98
Possibly, glucose utilization is disturbed due to insulin resistance as a
consequence of high levels of circulating catecholamines.99
Sympathetic nervous imaging
Myocardial uptake of 123I-metaiodobenzylguanidine (123I-MIBG,
imaged with SPECT) reflects myocardial sympathetic innervation
123I-MIBG is reduced for months in dysfunctional segments whereas
perfusion is almost normal, consistent with regional disturbance
of sympathetic neuronal activity.101 In the subacute phase of TTS,
123I-MIBG SPECT can be combined with SPECT perfusion imaging to
exclude ACS where both perfusion and innervation are reduced.
Position emission tomography imaging has also been used in TTS
for assessment of cardiac innervation with the use 11C
hydroxyephedrine.102
Complications and outcomes
Although TTS is generally considered a benign disease, contemporary
observations show that rates of cardiogenic shock and death are
comparable to ACS patients treated according to current guide-
lines.2,103–108 While TTS is a reversible condition, hemodynamic and
electrical instability during the acute phase expose patients to the risk
of serious adverse in-hospital events which occur in approximately
one-fifth of TTS patients (Figure 4).2 This substantial incidence of life-
threatening complications necessitates close monitoring and early
intervention in unstable TTS patients with risk stratification at diagno-
sis allowing triage to appropriate care.66 Parameters predicting ad-
verse in-hospital outcome include: physical trigger, acute neurologic
or psychiatric diseases, initial troponin >10 upper reference limit,
and admission LVEF <45%.2 Furthermore, male patients have an up
to three-fold increased rate of death and major adverse cardiac and
cerebrovascular events (MACCE)109 and more often had an underly-
ing critical illness, further contributing to the higher mortality.2 Sobue
et al.110 demonstrated that physical triggers and male gender are in-
dependent risk factors of in-hospital mortality in TTS. Data from the
Tokyo Coronary Care Unit Network revealed that high values of
BNP and white blood cell counts were also linked to higher rates of
in-hospital complications.111 Complications included cardiac death,
pump failure (Killip grade >_II), sustained ventricular tachycardia or
ventricular fibrillation (VT/VF), and advanced atrioventricular block
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(AV-block). In the study by Takashio et al.112 the magnitude and ex-
tent of ST-segment elevation with ECG were found to be independ-
ent predictors of in-hospital adverse events. However, those findings
were not confirmed by others. Common in-hospital complications
include cardiac arrhythmias,113 LVOTO,64 cardiogenic shock,2 ven-
tricular thrombus,114 pulmonary oedema,115 ventricular septal
defect,116 and free wall rupture.117 In addition, to the demographic
parameter of age >_75, echocardiographic parameters that predict ad-
verse in-hospital outcome (acute heart failure, cardiogenic shock, and
in-hospital mortality) include LVEF, E/e’ ratio, and reversible moderate
to severe MR. However, only reversible moderate to severe MR was
an independent predictor when considering cardiogenic shock and
death as the composite outcome in this study, in addition to heart
rate. Moreover, it has been demonstrated that high heart rate and low
systolic blood pressure are associated with increased mortality in
TTS.118 Along with the Charlson comorbidity index and systolic pul-
monary artery pressure, RV involvement is an independent predictor
of acute heart failure and of a composite endpoint including adverse
events, such as acute heart failure, cardiogenic shock, and in-hospital
mortality.119
Data on long-term survival are scarce. In 2007, Elesber et al.120 re-
ported that long-term mortality did not differ between a TTS popula-
tion and an age-, gender-, birth-, year-, and race-matched population.
While Sharkey et al.121 found that all-cause mortality during follow-
up exceeded a matched general population with most deaths occur-
ring in the first year. More recently, it has been reported that long-
term mortality of patients with TTS122 is similar to (Figure 5A) patients
with CAD.103 TTS patient data from the Swedish Angiography and
Angioplasty Registry (SCAAR) from 2009 to 2013 were compared
to data from patients with and without CAD, and demonstrated that
mortality rates for TTS were worse than in patients without CAD
and comparable to those of patients with CAD.103 In the largest TTS
registry to date, death rates are estimated to be 5.6% and rate of
MACCE 9.9% per-patient year (Figure 5B),2 suggesting that TTS is not
a benign disease. A recent study found that patients with the typical
TTS type have a comparable outcome to patients presenting with
the atypical type even after adjustment for confounders, suggesting
that both patient groups should be equally monitored in the long-
term.40 On the other hand, 1-year mortality differs between the two
groups, as it is driven by clinical factors including atrial fibrillation,
LVEF on admission <45%, and neurologic disorders, rather than by
Acute heart failure (12-45%)
LVOTO (10-25%)
Mitral regurgitation (14-25%)
Cardiogenic shock (6-20%)
Atrial fibrillation (5-15%)
LV-thrombus (2-8%)
Cardiac arrest (4-6%)
AV-block ~5%
Tachyarrhythmia (2-5%)
Bradyarrhythmia (2-5%)
Torsades-de-pointes (2-5%)
Death (1-4.5%)
Ventricular tachycardia/fibrillation ~3%
Acute ventricular septal defect <1%
Frequent
Moderate
Rare
In-hospital Complications
Figure 4 Overview of in-hospital complications according to their prevalence. AV, atrioventricular block; LV, left ventricle; LVOTO, left ventricu-
lar outflow tract obstruction.
Figure 5 Long-term outcome (5-years) of patients with TTS
compared to patients with and without CAD (A). Long-term out-
come (10-years) of patients with TTS (B). MACCE refers to a com-
posite of death from any cause, recurrence of takotsubo syndrome,
stroke or transient ischaemic attack, or myocardial infarction.
CAD, coronary artery disease; MACCE, major adverse cardiac and
cerebrovascular event; MI, myocardial infarction; TIA, transient
ischaemic attack; TSC, takotsubo stress cardiomyopathy. Reprinted
with permission from Tornvall et al.103 and Templin et al.2
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..TTS type.40 In a smaller study, predictive factors of long-term mortal-
ity in TTS were male sex, Killip class III/IV, and diabetes mellitus.122
The prognostic role of diabetes mellitus is controversial, as it is postu-
lated that it may exert a protective effect in TTS, given that the preva-
lence of diabetes mellitus in TTS is lower than expected for an age-
and sex-matched population.123 Some studies, though limited by
their population size and experimental design, suggest that patients
with diabetes mellitus have a more favourable in-hospital and 1-year
outcome.124,125
Arrhythmias
Cardiac arrhythmias are important determinants of short-term clin-
ical outcome.
Ventricular arrhythmias
Life-threatening ventricular arrhythmias, such as torsades de pointes,
VT, or VF occur in 3.0–8.6% and are a frequent cause of death.2,126–
128 Life-threatening ventricular arrhythmias occur most often in the
subacute phase (i.e. hospital days 2–4) and coincide with anterolateral
T-wave inversion and QT-interval prolongation.129 QTc prolonga-
tion at admission occurs in up to half of the patients.2 Most malignant
arrhythmic episodes are associated with a QTc >500 ms, with pause-
dependent torsades de pointes degenerating into VF.127,128,130 .
Figure 6 shows a patient with apical ballooning (A). On the third day
of hospitalization giant negative T-waves, marked QT prolongation,
and ‘R on T’ premature ventricular beats were noted on ECG (B).
Furthermore, pause-dependent (‘long-short sequence’) torsade-de-
pointes/ventricular fibrillation requiring electrical cardioversion were
recorded by telemetry (C).128 Accordingly, TTS should be regarded
as a type of acquired long QT syndrome with risk for malignant ar-
rhythmic events.128,130
Cardiac magnetic resonance findings reveal an association be-
tween transient myocardial oedema, as evidenced by T2-weighted
sequences, and dynamic T-wave inversion and QT prolonga-
tion.131,132 Thus, myocardial oedema may contribute to transmural
or regional (i.e. from the apex to the base of the LV) repolarization
inhomogeneity. QT prolongation thus reflects the delayed and dis-
persed ventricular repolarisation that predisposes to local re-
excitation and eventually to torsade de pointes or VF.131–133
Rarely, cardiac arrest is the initial presentation of TTS unrelated to
QT interval prolongation. The mechanism of these potentially lethal
arrhythmias is probably distinct from that encountered during the
subacute phase where acute catecholamine toxicity and/or myocar-
dial ischaemia play a primary role. In some cases, TTS may not repre-
sent the trigger for tachyarrhythmias, but rather the consequence of
the stress of cardiac arrest and/or resuscitation, which may include
administration of epinephrine.134
Other cardiac arrhythmias
New-onset paroxysmal or persistent atrial fibrillation occurs in 4.7%,
sinus-node dysfunction in 1.3%, and AV-block in 2.9%, most likely
due to neuro-autonomic imbalance, catecholamine stress, and
increased vagal tone.127,130,134
Recurrence
Patients who survive the initial event have a second event in approxi-
mately 5% of cases, mostly occurring 3 weeks to 3.8 years after the
first event.135 Recurrent TTS afflicts men and women and may occur
Figure 6 Arrhythmic complication in takotsubo syndrome. Left ventriculography (antero-posterior view) showing the typical apical ballooning pat-
tern with akinesia of the mid-apical segments and hyperkinesia of the basal segment (A). A 12-lead electrocardiogram recorded at the third day of
hospitalization showing giant negative T-waves in leads aVL, L1, L2, aVF and V4–V6, marked QT prolongation (QTc = 552 ms) and ‘R on T’ premature
ventricular beats (B). Telemetry recording of a pause-dependent (‘long-short sequence’) torsade-de-pointes/ventricular fibrillation, which required
electrical cardioversion (C). Reprinted with permission from Migliore et al.130
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..at any age including in childhood.78,136,137 Both the triggering event
and the ballooning pattern may differ during recurrent events.78
Some have postulated that an index TTS event may protect the af-
fected LV regions from recurrent involvement through a mechanism
akin to ischaemic ‘pre-conditioning’.138 However, detailed review of
published cases and clinical experience suggest that there are fre-
quent examples of recurrence in which the ballooning pattern is simi-
lar between episodes, thereby making this hypothesis unlikely.
Therapeutic management
Guidelines regarding TTS management are lacking as no prospective
randomized clinical trials have been performed in this patient popula-
tion. Therapeutic strategies are therefore based on clinical experi-
ence and expert consensus (evidence level C). Table 1 reviews
current data on medical management of TTS patients139 based of
retrospective analysis,2,140,141 meta-analysis,142,144 and case series.143
Figure 7 summarizes a proposed therapeutic management approach
for patients with TTS.
Pre-hospital treatment
As TTS is clinically difficult to distinguish from ACS, upon first presen-
tation patients should be transferred to a cardiology unit with imaging
capabilities and a cardiac catheterization laboratory and receive
guideline based treatment of ACS,105–108 in particular aspirin, heparin,
and if required morphine and oxygen. Patients with cardiogenic shock
or post cardiac arrest require intensive care. Electrocardiogram
monitoring is essential as a prolonged QT-interval may trigger malig-
nant ventricular arrhythmias (torsades de pointes) and AV-block
may occur.
Acute treatment
Takotsubo syndrome patients with cardiogenic shock, in particular
those with apical ballooning should be promptly evaluated for the
presence of LVOTO, which occurs in about 20% of cases.39 This
should be performed during angiography with LV pressure recording
during careful retraction of the pigtail catheter from the LV apex be-
yond the aortic valve. Similarly, a pressure gradient can be detected
and quantified using Doppler echocardiography using continuous
wave Doppler.145 Particularly, when using catecholamines serial
Doppler studies should be considered to detect an evolving pressure
gradient. In TTS patients treated with catecholamine drugs a 20%
mortality has been reported81; although this may represent a selec-
tion bias due to the initial presentation of the patients. Recently, it has
been suggested that the Ca2þ-sensitizer levosimendan could be used
safely and effectively in TTS as an alternative inotrope to catechol-
amine agents.143 Furthermore, beta-blockers may improve LVOTO,
but are contraindicated in acute and severe heart failure with low
LVEF, hypotension, and in those with bradycardia. Although evidence
is unproven, TTS patients with LVOTO may benefit from the If chan-
nel inhibitor ivabradine.146,147
As catecholamine levels are elevated in TTS, beta-blockers seem
to be reasonable until full recovery of LVEF, but trials supporting this
hypothesis are lacking. Animal experiments have shown that apical
ballooning is attenuated after administration of drugs with both alpha-
and beta-adrenoceptor blocking properties.148 In an animal model,
intravenous metoprolol improved epinephrine-induced apical bal-
looning.149 However, due to the potential risk of pause-dependent
torsades de pointes, beta-blockers should be used cautiously, espe-
cially in patients with bradycardia and QTc >500 ms. Angiotensin-
converting-enzyme inhibitors (ACEi) or angiotensin II receptor
blockers (ARB) may potentially facilitate LV recovery. Diuretics are
indicated in patients with pulmonary oedema. In addition, nitrogly-
cerin is useful to reduce LV and RV filling pressures and afterload in
....................................................................................................................................................................................................................
Table 1 Overview of retrospective analyses, meta-analyses, and case series of medical management for takotsubo
syndromea
Authors Study design No. of
patients
Outcome
measures
Follow-up time Medication Effect
Santoro et al.143 Case series 13 Adverse events During hospitalization Levosimendan Probably beneficial
Isogai et al.140 Retrospective 2110 Mortality 30 days b-Blockers Not beneficial
Dias et al.141 Retrospective 206 MACE During hospitalization Antiplatelet Beneficial
b-Blockers Not beneficial
Statins Not beneficial
ACEI Not beneficial
Templin et al.2 Retrospective 1118 Mortality 1 year b-Blockers Not beneficial
ACEI/ARB Beneficial
Santoro et al.142 Meta-analysis 511 Recurrence 24–60 months b-Blockers Not beneficial
ACEI/ARB Not beneficial
Aspirin Not beneficial
Statins Not beneficial
Singh et al.144 Meta-analysis 847 Recurrence 19–33 months b-Blockers Not beneficial
ACEI/ARB Beneficial
aReprinted with permission from Kato et al.139
ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; MACE, major adverse cardiac event.
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.the case of acute heart failure; however, the administration of nitro-
glycerin in the presence of LVOTO has been found to worsen the
pressure gradient and therefore should be avoided in this scenario
(see Figure 7).
QT-interval prolonging drugs should be used cautiously in the
acute phase because of the risk to induce torsades de pointes or ven-
tricular tachycardia and fibrillation.
Severe LV dysfunction with extended apical ballooning entails the
risk of an LV thrombus and subsequent systemic embolism. Although
evidence is lacking, anticoagulation with intravenous/subcutaneous
heparin would appear to be appropriate in such patients and post-
discharge oral anticoagulation or antiplatelet therapy may be con-
sidered on an individual, per-patient basis. As LV dysfunction and
ECG abnormalities are reversible, an implantable cardioverter-
defibrillator for primary or secondary prevention is of uncertain value
in TTS patients experiencing malignant ventricular arrhythmias.130,150
In case of excessive prolongation of the QT interval or life-
threatening ventricular arrhythmias a wearable defibrillator (life vest)
could be considered.151 The residual risk of malignant arrhythmic
events after recovery from TTS is unknown. A temporary
transvenous pacemaker is appropriate for those with haemodynami-
cally significant bradycardia.
Long-term treatment
The use of ACEi or ARB was associated with improved survival at
1-year follow-up even after propensity matching.2 In contrast, there
was no evidence of any survival benefit for the use of beta-blockers.2
Moreover, one-third of patients experienced a TTS recurrence dur-
ing beta-blockade2 suggesting that other receptors such as alpha-
receptors, that are more prevalent in the coronary microcirculation,
might be involved.
The prevalence of recurrent TTS is relatively low, consequently
conducting randomised trials of pharmacological agents to prevent
recurrence is challenging. Beta-blocker therapy after hospital dis-
charge does not appear to prevent recurrence,2,144 whereas ACEi or
ARB are associated with a lower prevalence of recurrence. The sig-
nificance of this observation remains uncertain and requires vali-
dation in other cohorts.
If concomitant coronary atherosclerosis is present, aspirin and sta-
tins are appropriate. As TTS mainly occurs in postmenopausal
Figure 7 Management of takotsubo syndrome. ACE, angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; AV-block, atrioventricu-
lar block; HF, heart failure; IABP, intra-aortic balloon pump; IV, intravenous; LV, left ventricle; LVAD, left ventricular assist device; LVD, left ventricular
dysfunction; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; NOAC, novel oral anticoagulant; QTc, QT-
time corrected for heart rate; RV, right ventricle; TTS, takotsubo syndrome; VA-ECMO, venoarterial extracorporeal membrane oxygenation; VF,
ventricular fibrillation; VT, ventricular tachycardia.
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women oestrogen supplementation in those with recurrence is ques-
tionable. In an animal model oestrogen supplementation partially
attenuated TTS,152 and chronic oestrogen supplementation after oo-
phorectomy improved the condition.153
Psychiatric disorders (e.g. depression, anxiety) are common in TTS
patients2,154 and those might benefit from a combined psycho-
cardiologic rehabilitation.155 Whether anti-depressants or other psy-
chiatric drugs might provide clinical benefit in such patients is
controversial.
Future directions
Over recent years research has shown that TTS is a much more het-
erogeneous condition than previously thought. Originally believed to
be a benign disease, studies have shown that TTS has morbidity and
mortality rates that are comparable to those of ACS.2,103 TTS can af-
fect many others aside from postmenopausal women with an emo-
tional trigger,2,135 as originally described, and can present as an
atypical type rather than apical ballooning.40 Still, there is much more
to be uncovered surrounding TTS and the underlying pathophysi-
ology of the syndrome.156
Key questions
Many questions need further investigation: Why are women affected
predominantly? What is the role of triggering factors in stress re-
sponses of the heart? Why do different TTS phenotypes exist?
Which patients are vulnerable to TTS or prone to recurrence? Is
there a genetic predisposition to TTS? What is the exact pathogen-
esis of TTS? Are there specific treatment options in the acute stage of
this life-threatening syndrome or to prevent recurrence? Additional
research needs to be conducted to answer these important
questions.
Prospective approaches
The link between the brain and heart seems to play a key role in TTS.
Additionally, studies on circulating miRNAs suggest there could be a
genetic aspect to the pathophysiology of TTS, and the predominance
of female patients suggests that TTS could be related to sex hor-
mones and the endocrine system. Takotsubo syndrome is more than
a cardiac disease, and it requires a new and interdisciplinary approach
to increase awareness among not only cardiologists, but physicians at
large. To establish evidence based strategies for effective TTS treat-
ment, randomized prospective trials will be necessary utilizing a large
number of patients from multicentre international consortia.
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